• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Salvage Strategies for Management of Testicular Tumors.睾丸肿瘤治疗的挽救策略
Indian J Surg Oncol. 2017 Sep;8(3):389-396. doi: 10.1007/s13193-016-0614-1. Epub 2017 Jun 6.
2
Organ-sparing approaches for testicular masses.保留睾丸的方法治疗睾丸肿块。
Nat Rev Urol. 2010 Aug;7(8):454-64. doi: 10.1038/nrurol.2010.100.
3
[Focal surgery in testis cancer: current state of the art].[睾丸癌的局部手术:当前技术水平]
Urologia. 2013 Sep-Dec;80(4):290-6. doi: 10.5301/RU.2013.11687. Epub 2013 Dec 16.
4
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results.睾丸肿瘤中冰冻切片分析引导下的器官保留方法:技术、可行性及长期结果
Urology. 2003 Sep;62(3):508-13. doi: 10.1016/s0090-4295(03)00465-5.
5
Testicular tumors in children.儿童睾丸肿瘤
J Pediatr Surg. 2001 Dec;36(12):1796-801. doi: 10.1053/jpsu.2001.28841.
6
Organ sparing surgery for malignant germ cell tumor of the testis.睾丸恶性生殖细胞肿瘤的保留器官手术。
J Urol. 2001 Dec;166(6):2161-5. doi: 10.1016/s0022-5347(05)65526-7.
7
Organ Sparing Surgery in Testicular Cancer睾丸癌的保留器官手术
8
The role of partial orchidectomy in the management of small testicular tumours: Fertility and endocrine function.部分睾丸切除术在小睾丸肿瘤治疗中的作用:生育和内分泌功能。
Andrology. 2020 Sep;8(5):988-995. doi: 10.1111/andr.12786. Epub 2020 Jun 22.
9
Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia .睾丸生殖细胞肿瘤和生殖细胞肿瘤形成中的睾丸保留策略。
Transl Androl Urol. 2020 Jan;9(Suppl 1):S24-S30. doi: 10.21037/tau.2019.07.22.
10
Testis Sparing Surgery of Small Testicular Masses: Retrospective Analysis of a Multicenter Cohort.保留睾丸的小睾丸肿块手术:多中心队列的回顾性分析。
J Urol. 2020 Apr;203(4):760-766. doi: 10.1097/JU.0000000000000579. Epub 2019 Oct 3.

本文引用的文献

1
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.改良化疗后腹膜后淋巴结清扫范围外转移性非精原细胞性生殖细胞肿瘤的发生率
J Clin Oncol. 2007 Oct 1;25(28):4365-9. doi: 10.1200/JCO.2007.11.2078.
2
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?对于化疗后残留肿瘤,是否总是需要进行双侧完全腹膜后淋巴结清扫?
Cancer. 2007 Sep 15;110(6):1235-40. doi: 10.1002/cncr.22898.
3
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.一项针对预后不良的转移性生殖细胞肿瘤患者的 III 期随机试验,比较常规剂量化疗联合或不联合大剂量化疗及自体造血干细胞救援作为一线治疗的效果。
J Clin Oncol. 2007 Jan 20;25(3):247-56. doi: 10.1200/JCO.2005.05.4528.
4
Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.一线序贯大剂量卡铂、依托泊苷和异环磷酰胺化疗联合外周血干细胞支持治疗晚期睾丸生殖细胞肿瘤患者的长期结果
Int J Urol. 2007 Jan;14(1):54-9. doi: 10.1111/j.1442-2042.2006.01655.x.
5
Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.根据国际生殖细胞癌协作组(IGCC)分类的非精原细胞性生殖细胞癌患者的生存率:基于荟萃分析的更新
Eur J Cancer. 2006 May;42(7):820-6. doi: 10.1016/j.ejca.2005.08.043. Epub 2006 Mar 30.
6
Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer.睾丸癌治疗中腹膜后淋巴结清扫术的长期疗效
World J Urol. 2006 Aug;24(3):267-72. doi: 10.1007/s00345-006-0060-8. Epub 2006 Mar 8.
7
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.一项针对转移性生殖细胞癌患者的TIP(紫杉醇、异环磷酰胺和顺铂)二线(BEP方案之后)挽救性化疗的II期试验:一项医学研究委员会试验。
Br J Cancer. 2005 Jul 25;93(2):178-84. doi: 10.1038/sj.bjc.6602682.
8
18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.18F-氟脱氧葡萄糖正电子发射断层扫描在化疗后生殖细胞肿瘤评估中的应用
Urology. 2004 Dec;64(6):1202-7. doi: 10.1016/j.urology.2004.07.024.
9
Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group.晚期生殖细胞肿瘤化疗后坏死的预测:德国睾丸癌研究组前瞻性多中心试验结果
J Urol. 2004 May;171(5):1835-8. doi: 10.1097/01.ju.0000119121.36427.09.
10
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.2-18氟脱氧-D-葡萄糖正电子发射断层扫描是化疗后精原细胞瘤中存活肿瘤的可靠预测指标:前瞻性多中心SEMPET试验的更新
J Clin Oncol. 2004 Mar 15;22(6):1034-9. doi: 10.1200/JCO.2004.07.188.

睾丸肿瘤治疗的挽救策略

Salvage Strategies for Management of Testicular Tumors.

作者信息

Chatterjee Smaranjit, Rawal Sudhir Kumar

机构信息

Department of Surgical Oncology and Uro-oncology, Rajeev Gandhi Cancer Institute and Research Centre, Rohini Sector 5, New Delhi, 110085 India.

出版信息

Indian J Surg Oncol. 2017 Sep;8(3):389-396. doi: 10.1007/s13193-016-0614-1. Epub 2017 Jun 6.

DOI:10.1007/s13193-016-0614-1
PMID:36118409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9478072/
Abstract

Testicular germ cell tumors (GCTs) comprise 2% of all human male malignancies and are the most common solid tumors in men between ages 15 and 35 years. Risk of contralateral testicular GCT is between 1 and 5%. Partial orchidectomy (PO) was originally described in 1984 by Richie. The evolving indications include metachronous tumors and tumor in solitary testicles. Also, small non-palpable lesions detected only by ultrasonography (USG) in asymptomatic patients is another indication. Salvagability is only chosen for tumors less than 2 cm in size. The key feature of PO is an inguinal approach with early vascular control using a rubber tourniquet before testicular mobilization into the field to avoid systemic tumor seeding. After, mass excision with a margin mandatory frozen section is done to assess adequacy of resection. Intra-op USG may be beneficial in small non-palpable lesions. Post op tumor markers are assessed and patients are taught self-examination of testis. Recent series shows that PO is safe and gives adequate oncological control. Carcinoma in situ (CIS) in the affected testis at PO or after testicular sparing surgery remains a challenge. At most centers, 20 Gy is recommended when adjuvant local radiation treatment is chosen to treat CIS. But this dose may hamper Androgen production. Radical orchiectomy remains the gold standard and should be discussed as part of informed consent. It is mandatory to highlight the risks of local recurrence and CIS, and treatment (observation, radiation, or completion orchiectomy) as well as the need for androgen supplementation and fertility risks before choosing testicular salvage procedures.

摘要

睾丸生殖细胞肿瘤(GCTs)占人类男性所有恶性肿瘤的2%,是15至35岁男性中最常见的实体瘤。对侧睾丸发生GCT的风险在1%至5%之间。部分睾丸切除术(PO)最初由里奇于1984年描述。其适应证不断演变,包括异时性肿瘤和单睾丸中的肿瘤。此外,无症状患者中仅通过超声检查(USG)发现的不可触及的小病变是另一个适应证。仅对直径小于2 cm的肿瘤选择保留睾丸手术。PO的关键特征是采用腹股沟入路,在将睾丸移至手术视野之前,先用橡胶止血带早期控制血管,以避免肿瘤细胞播散至全身。之后,进行肿块切除并进行切缘强制冰冻切片检查,以评估切除是否彻底。术中超声检查对不可触及的小病变可能有益。术后评估肿瘤标志物,并教会患者自我检查睾丸。最近的系列研究表明,PO是安全的,并且能提供足够的肿瘤学控制。PO或保留睾丸手术后,患侧睾丸的原位癌(CIS)仍然是一个挑战。在大多数中心,选择辅助局部放疗治疗CIS时,推荐剂量为20 Gy。但这个剂量可能会影响雄激素的产生。根治性睾丸切除术仍然是金标准,应作为知情同意的一部分进行讨论。在选择保留睾丸手术之前,必须强调局部复发和CIS的风险、治疗方法(观察、放疗或根治性睾丸切除术)以及雄激素补充的必要性和生育风险。